Novo Nordisk and Oxford University team up to develop novel treatments for rheumatoid arthritis
24 April 2012 | By Novo Nordisk
Novo Nordisk and the Oxford University announce a new partnership...
List view / Grid view
24 April 2012 | By Novo Nordisk
Novo Nordisk and the Oxford University announce a new partnership...
23 April 2012 | By AstraZeneca
Deal includes lead product lesinurad in Phase III development for gout...
23 April 2012 | By Takeda Pharmaceutical Company Limited
For the treatment of iron deficiency anaemia in adult chronic kidney disease patients...
23 April 2012 | By AstraZeneca
In combination with other glucose-lowering medicinal products including insulin...
23 April 2012 | By GlaxoSmithKline Plc
Announcement follows divestment of brands in USA, Canada & Europe...
23 April 2012 | By Novo Nordisk
Two studies show a significant reduction in the rates of nocturnal hypoglycaemia by 25%, compared to insulin glargine...
23 April 2012 | By Amgen
Amgen has announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away...
20 April 2012 | By Sanofi
Full CARE-MS II results for Alemtuzumab to be unveiled...
20 April 2012 | By Novartis
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer...
20 April 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and AstraZeneca announced that the CHMP of the EMA has recommended approval of FORXIGA® (dapagliflozin) tablets...
20 April 2012 | By Abbott
Abbott has received U.S. FDA clearance to use its iFS Advanced Femtosecond Laser...
19 April 2012 | By Sanofi
Fox Foundation to sponsor a clinical trial to study Sanofi compound...
18 April 2012 | By Boehringer Ingelheim
1 Mission 1 Million announces plans to launch an exciting new phase of the initiative...
18 April 2012 | By Teva Pharmaceutical Industries Ltd
TEVA announced new data from the Company's expanding CNS portfolio...
18 April 2012 | By Roche
Roche released the following statement based on preliminary estimates...